Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. METHODS: We enrolled 459 patients with chronic heart failure of New York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for patients with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin level <100 microg per liter or between 100 and 299 microg per liter, if the transferrin saturation was <20%), and a hemoglobin level of 95 to 135 g per liter. Patients were randomly assigned, in a 2:1 ratio, to receive 200 mg of intravenous iron (ferric carboxymaltose) or saline (placebo). The primary end points were the self-reported Patient Global Assessment and NYHA functional class, both at week 24. Secondary end points included the distance walked in 6 minutes and the health-related quality of life. RESULTS: Among the patients receiving ferric carboxymaltose, 50% reported being much or moderately improved, as compared with 28% of patients receiving placebo, according to the Patient Global Assessment (odds ratio for improvement, 2.51; 95% confidence interval [CI], 1.75 to 3.61). Among the patients assigned to ferric carboxymaltose, 47% had an NYHA functional class I or II at week 24, as compared with 30% of patients assigned to placebo (odds ratio for improvement by one class, 2.40; 95% CI, 1.55 to 3.71). Results were similar in patients with anemia and those without anemia. Significant improvements were seen with ferric carboxymaltose in the distance on the 6-minute walk test and quality-of-life assessments. The rates of death, adverse events, and serious adverse events were similar in the two study groups. CONCLUSIONS: Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov number, NCT00520780).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, parenteral iron substitution has been found to improve the clinical course of CHF in patients with coexisting ID [22–24].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [24]
In the citing paper
“We are aware that anemia is a complication of iron deficiency, though not the only one, since other tissues/organs may be iron-depleted before anemia develops, as occurs in chronic heart failure.75”
From Iron metabolism and iron disorders revisited in the hepcidin era (2020) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Regression Models for Ordinal Data
McCullagh, P. (1980) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1980.tb01109.x · Cited by 4,453
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors/Task Force Members, Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,512
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Trends in Heart Failure Incidence and Survival in a Community-Based Population
Roger, V. L. (2004) · JAMA · doi:10.1001/jama.292.3.344 · Cited by 1,600
Jessup, M., & Brozena, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021498 · Cited by 1,564
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
Haas, J. D., & Brownlie, T. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.2.676s · Cited by 1,186
Research works printed but not linked: 4
- Fairbanks V, Beutler E. Iron deficiency. In: Beutler E, ed. Williams hematology. 6th ed. New York: McGraw-Hill, 2001:295-304, 447-70.
- Davies KJ, 1982, Am J Physiol, 242, E418
- Usmanov RI, 2008, J Nephrol, 21, 236
- Ganzoni AM, 1970, Schweiz Med Wochenschr, 100, 301
Cited by
Items 501–600 of 1,002
Fitzsimons, S., Yeo, T. J., Ling, L. H., Sim, D., Leong, K. T. G., Yeo, P. S. D., Ong, H. Y., Jaufeerally, F. R., Ng, T. P., Poppe, K., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13617 · Cited by 39
“This was chosen as, to date, it is the most widely assessed definition of ID in HF patients.(9,10) We also assessed a second definition of ID —‘tsat < 20%’ (IDTsat).”
BackgroundMethodWaldum, B., Westheim, A. S., Sandvik, L., Flønæs, B., Grundtvig, M., Gullestad, L. L., Hole, T., & Os, I. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.10.864 · Cited by 44
Vitamin B12and folate deficiency in chronic heart failure
van der Wal, H. H., Colet, J. C., Klip, I. T., Enjuanes, C., Beverborg, N. G., Voors, A. A., Banasiak, W., van Veldhuisen, D. J., Bruguera, J., Ponikowski, P. P., et al. (2014) · Heart · doi:10.1136/heartjnl-2014-306022 · Cited by 37
Self-citationAlayón, C. G., Crespo, C. P., Pedrosa, S. M., Benítez, J. M., Flores, E. I., Rodríguez, I. S., Medina, R., & García-Sánchez, V. (2017) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2017.07.011 · Cited by 37
McQuilten, Z., Thảo, L. T. P., Pasricha, S., Artz, A. S., Bailey, M., Chan, A. T., Cohen, H. J., Lockery, J. E., Murray, A. M., Nelson, M. R., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m23-0675 · Cited by 40
Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency
Cheema, B. S., Chokshi, A. K., Orimoloye, O. A., & Ardehali, H. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.431 · Cited by 47
The investigation and treatment of secondary anaemia
Davis, S. L., & Littlewood, T. J. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.10.003 · Cited by 44
Kang, J., Park, J., Lee, J. M., Park, J. J., & Choi, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.187 · Cited by 39
Theidel, U., Väätäinen, S. T., Martikainen, J. A., Soini, E. J., Hardt, T., & Doehner, W. (2017) · ESC Heart Failure · doi:10.1002/ehf2.12179 · Cited by 36
Long-term management of end-stage heart failure
Habal, M. V., & Garan, A. R. (2017) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2017.07.003 · Cited by 46
Iron deficiency in chronic and acute heart failure: A contemporary review on intertwined conditions
Cunha, G., Rocha, B. M. L., & Falcão, L. M. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.04.013 · Cited by 36
Godde, K., & Hens, S. M. (2021) · American Journal of Physical Anthropology · doi:10.1002/ajpa.24244 · Cited by 40
Schuuring, M. J., Treskes, R. W., Castiello, T., Jensen, M. T., Casado-Arroyo, R., Neubeck, L., Lyon, A. R., Keser, N., Rucinski, M., Marketou, M. E., et al. (2024) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztae064 · Cited by 43
Niehaus, E. D., Malhotra, R. K., Cocca-Spofford, D., Semigran, M. J., & Lewis, G. D. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.05.006 · Cited by 35
Borstlap, W. A. A., Buskens, C. J., Tytgat, K. M. A. J., Tuynman, J. B., Consten, E. C. J., Tolboom, R. C., Heuff, G., van Geloven, N., van Wagensveld, B. A., Wientjes, C. A., et al. (2015) · BMC Surgery · doi:10.1186/s12893-015-0065-6 · Cited by 35
Geissler, R. G., Rotering, H., Buddendick, H., Franz, D., Bunzemeier, H., Roeder, N., Kwiecien, R., Sibrowski, W., Scheld, H. H., Martens, S., et al. (2015) · Transfusion Medicine and Hemotherapy · doi:10.1159/000377691 · Cited by 43
Anemia is a mortality prognostic factor in patients initially hospitalized for acute heart failure
Amicis, M. M. D., Chivite, D., Corbella, X., Cappellini, M. D., & Formiga, F. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1637-5 · Cited by 35
What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines
Bozkurt, B. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0978-7 · Cited by 41
Iron deficiency anemia, population health and frailty in a modern Portuguese skeletal sample
Hens, S. M., Godde, K., & Macak, K. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213369 · Cited by 40
“Furthermore, because iron deficiency has been associated with inflammatory conditions [13], it may predispose an individual to infections and heart failure [16].”
BackgroundTanaka, S., Kamiya, K., Saito, H., Saito, K., Ogasahara, Y., Maekawa, E., Konishi, M., Kitai, T., IWATA, K., Jujo, K., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13140 · Cited by 37
Tajes, M., Díez‐López, C., Enjuanes, C., Moliner, P., Ferreiro, J. L., Garay, A., Jiménez‐Marrero, S., Yun, S., Sosa, S. G., Alcoberro, L., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00605-5 · Cited by 38
“Although the unequivocal benefits of intravenous iron may be related to a peripheral effect [14, 28], recent studies support a cardiac-centered hypothesis.”
Khan, M. S., Anker, S. D., Friede, T., Jankowska, E. A., Metra, M., Piña, I. L., Coats, A. J. S., Rosano, G. M. C., Roubert, B., Goehring, U.-M., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.10.423 · Cited by 47
Self-citationMcKeag, N. A., McKinley, M. C., Harbinson, M., McGinty, A., Neville, C. E., Woodside, J. V., & McKeown, P. (2016) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000322 · Cited by 38
Neglected Comorbidity of Chronic Heart Failure: Iron Deficiency
Manceau, H., Ausseil, J., Masson, D., Feugeas, J., Sablonnière, B., Guieu, R., Puy, H., & Peoc’h, K. (2022) · Nutrients · doi:10.3390/nu14153214 · Cited by 37
Kennedy, N. A., Achebe, M. M., Biggar, P. H., Pöhlmann, J., & Pollock, R. F. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01548-2 · Cited by 42
Identification of three mechanistic pathways for iron-deficient heart failure
Packer, M., Anker, S. D., Butler, J., Cleland, J. G. F., Kalra, P. R., Mentz, R. J., & Ponikowski, P. P. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae284 · Cited by 43
“Two double-blind, placebo-controlled trials—FAIR-HF and CONFIRM-HF 116,117 —evaluated the effect of ferric carboxymaltose on symptoms, functional capacity, and health status after 24 and 52 weeks, respectively.”
BackgroundMethodSelf-citationHeart failure with reduced ejection fraction
Cannata, A. N., Crespo-Leiro, M. G., Bromage, D. I., Ruschitzka, F., & McDonagh, T. A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01851-3 · Cited by 44
Management of Heart Failure With Preserved Ejection Fraction: A Review
Nanayakkara, S., & Kaye, D. M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.005 · Cited by 45
McMurray, J. J. V., Adamopoulos, S. N., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G. S., Fonseca, C., Sánchez, M. Á. G., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.08.003 · Cited by 56
Self-citationTalbot, N. P., Smith, T. G., Privat, C., Nickol, A. H., Rivera, M. C., Lèon‐Velarde, F., Dorrington, K. L., & Robbins, P. A. (2011) · High Altitude Medicine & Biology · doi:10.1089/ham.2011.1005 · Cited by 39
Mistry, R. H., Hosoya, H., Kohut, A. R., & Ford, P. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03777-w · Cited by 37
Shin, H. W., Go, D. Y., Lee, S. W., Choi, Y. J., Ko, E., You, H. S., & Jang, Y. (2021) · Medicine · doi:10.1097/md.0000000000024571 · Cited by 36
“The efficacy and tolerability of FCM have been validated in the treatment of IDA in patients with irritable bowel disease,([36]) and most recently in chronic heart failure.([37]) In our meta-analysis, posttreatment Hb and ferritin levels were higher in FCM group compared with the IS group.”
ResultImplications of Iron Deficiency in STEMI Patients and in a Murine Model of Myocardial Infarction
Inserte, J., Barrabés, J. A., Aluja, D., Otaegui, I., Bañeras, J., Castellote, L., Sánchez, A., Rodríguez-Palomares, J. F., Pineda, V., Miró‐Casas, E., et al. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.05.004 · Cited by 39
“ID was defined as ferritin level <100 mg/L or 100-299 mg/L if transferrin saturation was <20% (1,2).”
BackgroundMethodKramer, T., Wißmüller, M., Natsina, K., Gerhardt, F., ten Freyhaus, H., Dumitrescu, D., Viethen, T., Hellmich, M., Baldus, S. E., & Rosenkranz, S. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12764 · Cited by 39
Bailie, G. R. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1296303 · Cited by 43
Rocha, B. M. L., & Falcão, L. M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.259 · Cited by 39
Cohen, C. T., & Powers, J. M. (2024) · Advances in Nutrition · doi:10.1016/j.advnut.2024.100215 · Cited by 83
“Adults with heart failure have also demonstrated improved clinical outcomes as well as health-related quality of life following IV iron therapy [83,84].”
BackgroundHildebrandt, P. R., Bruun, N. E., Nielsen, O. W., Pantev, E., SHIVA, F., Videbæk, L. M., Wikström, G., & Thomsen, L. L. (2010) · Transfusion Alternatives in Transfusion Medicine · doi:10.1111/j.1778-428x.2010.01145.x · Cited by 33
Craenenbroeck, E. M. V., Conraads, V. M., Greenlaw, N., Gaudesius, G., Mori, C., Ponikowski, P. P., & Anker, S. D. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft068 · Cited by 34
Self-citationAnguita, M. P., Colet, J. C., Almenar, L., Crespo, M., Delgado, J. F., González-Costello, J., Hernández‐Madrid, A., Manito, N., de la Sota, E. P., Segovia, J. R., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.07.013 · Cited by 33
Blood conservation in cardiac surgery
Blaudszun, G., Butchart, A. G., & Klein, A. A. (2017) · Transfusion Medicine · doi:10.1111/tme.12475 · Cited by 42
“Intravenous iron is an alternative and has been shown to be effective and safe (Anker et al., 2009).”
BackgroundIntravenous iron therapy for non-anaemic, iron-deficient adults
Miles, L. F., Litton, E., Imberger, G. L., & Story, D. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013084.pub2 · Cited by 39
“Concentration of haemoglobin, taken at the end of follow-up: Anker 2009 described haemoglobin concentration at 24 weeks for intervention (133 ± 1.0 g/L) and control (132 ± 1.0 g/L) groups.”
BackgroundMethodInfluentialBuilding a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America
Greene, S. J., Adusumalli, S., Albert, N. M., Hauptman, P. J., Rich, M. W., Heidenreich, P. A., & Butler, J. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.10.008 · Cited by 36
Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events
Regan, J. A., Truby, L., Tahir, U. A., Katz, D. H., Nguyen, M., Kwee, L. C., Deng, S., WILSON, J. G., Mentz, R. J., Kraus, W. E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24226-1 · Cited by 35
McKeag, N. A., McKinley, M. C., Harbinson, M., NOAD, R. L., Dixon, L. H., McGinty, A., Neville, C. E., Woodside, J. V., & McKeown, P. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2013.12.008 · Cited by 34
Howard, L., Watson, G. M. J., Wharton, J., Rhodes, C. J., Chan, K., Khengar, R. H., Robbins, P. A., Kiely, D. G., Condliffe, R. A., Elliott, C. A., et al. (2013) · Pulmonary Circulation · doi:10.4103/2045-8932.109923 · Cited by 38
Advances in management of heart failure
Heidenreich, P. A., & Sandhu, A. T. (2024) · BMJ · doi:10.1136/bmj-2023-077025 · Cited by 44
Effects of postoperative intravenous iron on transfusion requirements after lower limb arthroplasty
Múñoz, M., Naveira, E., Seara, J., & Cordero, J. (2012) · British Journal of Anaesthesia · doi:10.1093/bja/aes012 · Cited by 32
Solal, A. C., Leclercq, C., Mebazaa, A., de Groote, P., Damy, T., Isnard, R., & Galinier, M. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2014.07.049 · Cited by 38
Getting to the “Heart” of Cardiac Disease by Decreasing Mitochondrial Iron
Chang, H., Shapiro, J. S., & Ardehali, H. (2016) · Circulation Research · doi:10.1161/circresaha.116.309746 · Cited by 32
Nunes, A. R., & Tata, M. (2017) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2016.12.005 · Cited by 47
Bruns, E. R. J., Borstlap, W. A. A., van Duijvendijk, P., van der Zaag–Loonen, H. J., Buskens, C. J., Munster, B. C. V., Bemelman, W. A., & Tanis, P. J. (2019) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001360 · Cited by 35
Aizpurua, A. B., Wijk, S. S., Rocca, H. B., Henkens, M. T. H. M., Weerts, J., Spanjers, M. H. A., Knackstedt, C., & van Empel, V. P. M. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13204 · Cited by 38
“All in all, the results of our study show that although ID plays a role, ID it is not independently associated with impaired exercise capacity in HFpEF.”
BackgroundInfluentialIron Deficiency in CKD Without Concomitant Anemia
Wish, J. B., Anker, S. D., Butler, J., Cases, A., Stack, A. G., & Macdougall, I. C. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.07.032 · Cited by 36
“In both trials, ID was defined as ferritin <100 ng/ml or ferritin between 100 ng/ml and 300 mg/l if TSAT was <20%.(56,57) In the 52-week CONFIRM-HF trial, the median total dose of FCM iron was 1500 mg (range: 500–3500 mg).”
MethodSelf-citationTowards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases
Cacoub, P., Choukroun, G. J., Solal, A. C., Luporsi, É., Peyrin‐Biroulet, L., Peoc’h, K., Andrieu, V., Lasocki, S., Puy, H., & Trochu, J. (2022) · Nutrients · doi:10.3390/nu14051039 · Cited by 36
“This definition of ID in HF—ferritin concentration <100 g/L (absolute ID) or ferritin concentration 100–299 μg/L and TSAT < 20% (functional ID)—is often referred to as the “FAIR-HF criteria” because of the pivotal FAIR-HF trial [42].”
BackgroundRole of Iron Deficiency in Heart Failure—Clinical and Treatment Approach: An Overview
Singer, C. E., Vasile, C. M., Popescu, M., Popescu, A. I. S., Mărginean, I. C., Iacob, G. A., Popescu, M. D., & Mărginean, C. M. (2023) · Diagnostics · doi:10.3390/diagnostics13020304 · Cited by 45
“[51] published a meta-analysis including several controlled studies [25,52,53] in which the effectiveness of intravenous iron administration was compared in 370 patients versus 224 controls, with noticeable favorable results in the treated group of patients, regarding improvement of quality of life, NYHA class improve…”
MethodFilippatos, G. S., Ponikowski, P. P., Farmakis, D. T., Anker, S. D., Butler, J., Fabien, V., Kirwan, B., Macdougall, I. C., Metra, M., Rosano, G. M. C., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.060757 · Cited by 32
Self-citationKao, D. P., Kreso, E., Fonarow, G. C., & Krantz, M. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.08.046 · Cited by 35
Simbaqueba, C., Shrestha, K. L., Patarroyo, M. M., Troughton, R. W., Borowski, A. G., Klein, A. L., & Tang, W. H. W. (2012) · Congestive Heart Failure · doi:10.1111/chf.12010 · Cited by 30
Management of Noncardiac Comorbidities in Chronic Heart Failure
Chong, V., Singh, J. S., Parry, H., Saunders, J., Chowdhury, F., MANCINI, D. M., & Lang, C. C. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12141 · Cited by 36
Contemporary Strategies in the Diagnosis and Management of Heart Failure
Dunlay, S. M., Pereira, N. L., & Kushwaha, S. S. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.01.004 · Cited by 35
McMurray, J. J. V., Anand, I. S., Díaz, R., Maggioni, A. P., O’Connor, C. M., Pfeffer, M. A., Solomon, S. D., Tendera, M., van Veldhuisen, D. J., Albizem, M. B., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs204 · Cited by 34
Anemia and Iron Deficiency in Heart Failure
Magrì, D., Martino, F. D., Moscucci, F., Agostoni, P., & Sciomer, S. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.02.005 · Cited by 40
Inpatient management of acute decompensated heart failure
Raj, L. M., Maidman, S. D., & Adhyaru, B. B. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136742 · Cited by 36
Ajayi, A. A. L., Sofowora, G. G., & Ladipo, G. O. A. (2020) · Journal of the National Medical Association · doi:10.1016/j.jnma.2020.02.003 · Cited by 44
Khan, M. S., Usman, M., von Haehling, S., Doehner, W., & Coats, A. J. S. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13146 · Cited by 31
Heart Failure Hospitalization Risk associated with Iron Status in Veterans with CKD
Cho, M. E., Hansen, J. L., Sauer, B. C., Cheung, A. K., Agarwal, A., & Greene, T. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.15360920 · Cited by 33
Recent advances in pharmacological treatment of heart failure
Iacoviello, M., Palazzuoli, A., & Gronda, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13624 · Cited by 39
Boots, J. M. M., & Quax, R. A. M. (2022) · Drug Safety · doi:10.1007/s40264-022-01216-w · Cited by 37
Patient-Reported Outcomes in Heart Failure: Existing Measures and Future Uses
Thompson, L. E., Bekelman, D. B., Allen, L. A., & Peterson, P. N. (2015) · Current Heart Failure Reports · doi:10.1007/s11897-015-0253-9 · Cited by 34
Epidemiology of Anemia in Heart Failure
Tang, W. H. W., & Yeo, P. S. D. (2010) · Heart Failure Clinics · doi:10.1016/j.hfc.2010.03.007 · Cited by 37
Neuerungen der ESC-Leitlinien zur akuten und chronischen Herzinsuffizienz 2016
Oeing, C. U., Tschöpe, C., & Pieske, B. M. (2016) · Herz · doi:10.1007/s00059-016-4496-3 · Cited by 39
Zeng, J., Zhu, Y., Zhao, W., Wu, M., Huang, H., Huang, H., Wu, C., Zhou, X., Zhou, S., Wang, C., et al. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07176-0 · Cited by 30
Absolute and functional iron deficiency: Biomarkers, impact on immune system, and therapy
Iriarte‐Gahete, M., Tarancón‐Díez, L., Garrido‐Rodríguez, V., Leal, M., & Pacheco, Y. M. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101227 · Cited by 43
Palazzuoli, A., Ruocco, G. M., Pellegrini, M., Gori, C. D., Castillo, G. D., Nuti, R., & Giordano, N. G. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s61551 · Cited by 32
Anemia and Iron Deficiency in Heart Failure
Arora, N. P., & Ghali, J. K. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.11.002 · Cited by 34
Deranged iron status in psoriasis: the impact of low body mass
Ponikowska, M., Tupikowska, M., Kasztura, M., Jankowska, E. A., & Szepietowski, J. C. (2015) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12061 · Cited by 38
Manito, N., Cerqueiro, J. M., Colet, J. C., García‐Pinilla, J. M., Franco, Á. G., Amorós, J. G., Peraira, J. R., & Manzano, L. (2016) · Revista Clínica Española · doi:10.1016/j.rce.2016.08.001 · Cited by 33
Chau, M., Richards, T., Evans, C., Butcher, A., Collier, T. J., & Klein, A. A. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014872 · Cited by 31
Iron Deficiency and Long-Term Mortality in Elderly Patients With Acute Coronary Syndrome
González, J., Miñana, G., Núñez, J. E., Núñez, E., Ruíz, V., García‐Blas, S., Bonanad, C., Mollar, A., Valero, E., Amiguet, M., et al. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0021 · Cited by 32
Sindone, A. P., Doehner, W., & Colet, J. C. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14177 · Cited by 30
Mollace, A., Macrì, R., Mollace, R., Tavernese, A., Gliozzi, M., Musolino, V., Carresi, C., Maiuolo, J., Nicita, M., Caminiti, R., et al. (2022) · Nutrients · doi:10.3390/nu14235057 · Cited by 31
Iron status in women with infertility and controls: a case-control study
Holzer, I., Ott, J., Beitl, K., Mayrhofer, D., Heinzl, F., Ebenbauer, J., & Parry, J. P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1173100 · Cited by 43
“Moreover, evidence suggests some conditions respond to iron treatment despite ferritin levels above 30 (33, 34).”
BackgroundPels, A., & Ganzevoort, W. (2015) · Obstetrics and Gynecology International · doi:10.1155/2015/728952 · Cited by 33
Iron, oxygen, and the pulmonary circulation
Frise, M. C., & Robbins, P. A. (2015) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00179.2015 · Cited by 35
The pale evidence for treatment of iron-deficiency anaemia in older people
Soiza, R. L., Donaldson, A. I. C., & Myint, P. K. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618769568 · Cited by 41
IV iron formulations and use in adults
Doren, L. V., & Auerbach, M. (2023) · Hematology · doi:10.1182/hematology.2023000495 · Cited by 40
Clinical, Laboratory, and Pacing Predictors of CRT Response
Kandala, J., Altman, R., Park, M. Y., & Singh, J. P. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9352-0 · Cited by 30
for the RAID-HF (Registry Analysis of Iron Deficiency-Heart Failure) Study Group, Wienbergen, H., Pfister, O., Hochadel, M., Fach, A., Backhaus, T., Bruder, O., Remppis, B. A., Maeder, M. T., von Scheidt, W., et al. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1327-y · Cited by 34
Chronic Use of Proton-Pump Inhibitors and Iron Status in Renal Transplant Recipients
Douwes, R. M., Neto, A. W. G., Eisenga, M. F., Vinke, J. S. J., de Borst, M. H., van den Berg, E., Berger, S. P., Touw, D. J., Hak, E., Blokzijl, H., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091382 · Cited by 31
“Iron deficiency was defined as transferrin saturation (TSAT) 20% and ferritin 300 µ g / L, as described in literature previously and commonly used in patients with pro-inflammatory conditions, such as chronic heart failure and chronic kidney disease [3,17–19].”
MethodChung, Y. J., Swietach, P., Curtis, M. K., Ball, V., Robbins, P. A., & Lakhal‐Littleton, S. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.616920 · Cited by 34
Goel, H., Hirsch, J. R., Deswal, A. M., & Hassan, S. A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00960-1 · Cited by 29
von Haehling, S., & Anker, S. D. (2011) · Contributions to nephrology · doi:10.1159/000327342 · Cited by 29
Self-citationHofmarcher, T., & Borg, S. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1029491 · Cited by 34
Decker, I., Ghosh, S., COMHAIR, S. A. A., Farha, S., Tang, W. H. W., Park, M. M., Wang, S., Lichtin, A. E., & ERZURUM, S. C. (2011) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2011.00301.x · Cited by 29
Núñez, J. E., Domínguez, E., Ramón, J., Núñez, E., Sanchís, J. M., Santas, E., Heredia, R., González, J., Miñana, G., López, L., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.01.187 · Cited by 29
The interplay between iron and oxygen homeostasis with a particular focus on the heart
Lakhal‐Littleton, S., & Robbins, P. A. (2017) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00237.2017 · Cited by 30
Reinisch, W., Chowers, Y., Danese, S., Dignass, A. U., Gomollón, F., Nielsen, O. H., Lakatos, P. L., Lees, C. W., Lindgren, S. C., Lukáš, M., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12493 · Cited by 27
Shim, J., Kim, M. Y., Kim, Y. J., Lee, Y. B., Lee, J. J., Jun, J. K., Shin, J. C., Cho, Y. K., Lee, K. Y., Kim, A., et al. (2018) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-018-1817-y · Cited by 31
Neef, V., Baumgarten, P., Noone, S., Piekarski, F., Triphaus, C., Kleinerüschkamp, A., Helmer, P., Messroghli, L., Zacharowski, K. D., Choorapoikayil, S., et al. (2022) · Blood transfusion · doi:10.2450/2021.0058-21 · Cited by 28
Metadata
- Authors
- Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., Kirwan, B.-A., Mori, C., von Eisenhart Rothe, B., Pocock, S. J., Poole-Wilson, P. A., & Ponikowski, P.
- Affiliations
- Stavanger University Hospital (NO)
- Lund University (SE)
- University of Bergen (NO)
- Medizinische Hochschule Hannover (DE)
- University Hospital Zurich (CH)
- Pirogov Russian National Research Medical University (RU)
- State Oil Company of Azerbaijan Republic (Azerbaijan) (AZ)
- Vifor Pharma (Switzerland) (CH)
- London School of Hygiene & Tropical Medicine (GB)
- Imperial College London (GB)
- Wroclaw Medical University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-17
- Volume
- 361
- Issue
- 25
- Pages
- 2436-2448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2148669301
- Cited by
- 2,083
- References
- 26
- Citations by year
- 2026: 101 · 2025: 131 · 2024: 145 · 2023: 156 · 2022: 162 · 2021: 190 · 2020: 128 · 2019: 129 · 2018: 113 · 2017: 133 · 2016: 101 · 2015: 115 · 2014: 102 · 2013: 93 · 2012: 106
- FWCI
- 62.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Bedfordshire Repository (University of Bedfordshire) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Teva Pharmaceutical Industries
- Vifor Pharma
- Servier
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- ferric carboxymaltose, intravenous iron, chronic heart failure, iron deficiency, anemia, reduced left ventricular ejection fraction, NYHA functional class, symptom improvement, functional capacity, 6-minute walk test, health-related quality of life, ferritin, transferrin saturation, adverse events, mortality, serious adverse events, iron deficiency anemia
- MeSH terms
- Iron Deficiencies, Aged, Chronic Disease, Female, Ferric Compounds, Ferritins, Follow-Up Studies, Heart Failure, Hematinics, Humans, Male, Maltose, Quality of Life, Stroke Volume, Ventricular Dysfunction, Left, Anemia, Iron-Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.